List of Studies ( Metabolite:Penicillin G)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004182 | AN006944 | Metabolomics of ASCL1-high and ASCL1-low SCLC cells in mouse models | Cultured cells | Mouse | Cancer | CECAD Research Center | LC-MS |
| ST004182 | AN006945 | Metabolomics of ASCL1-high and ASCL1-low SCLC cells in mouse models | Cultured cells | Mouse | Cancer | CECAD Research Center | LC-MS |
| ST004153 | AN006895 | Multi-omics Study of Small Intestine Adaptation After Total Colectomy in a Rat model | Feces | Rat | Shanghai Jiao Tong University | LC-MS | |
| ST003745 | AN006150 | Screen potential marker proteins influencing spermatogenesis in the testes of Shandong Black Cattle bulls via multi-omics integrated analysis. | Testes | Cattle | Qingdao Agricultural University | LC-MS | |
| ST003622 | AN005951 | A multi-omic census reveals obesity-associated microRNA miR-let-7 as novel instigator of adipose mitochondrial dysfunction and of intergenerational metabolic decline. | Blood | Mouse | Obesity | University of Southern Denmark | LC-MS |
| ST003622 | AN005952 | A multi-omic census reveals obesity-associated microRNA miR-let-7 as novel instigator of adipose mitochondrial dysfunction and of intergenerational metabolic decline. | Blood | Mouse | Obesity | University of Southern Denmark | LC-MS |
| ST003436 | AN005645 | Pharmacokinetics of Fasnall in NSG mice | Blood | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005645 | Pharmacokinetics of Fasnall in NSG mice | Brain | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005645 | Pharmacokinetics of Fasnall in NSG mice | Heart | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005645 | Pharmacokinetics of Fasnall in NSG mice | Liver | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005646 | Pharmacokinetics of Fasnall in NSG mice | Blood | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005646 | Pharmacokinetics of Fasnall in NSG mice | Brain | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005646 | Pharmacokinetics of Fasnall in NSG mice | Heart | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005646 | Pharmacokinetics of Fasnall in NSG mice | Liver | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003435 | AN005643 | Metabolomics analysis of zebrafish embryos treated with rotenone, Fasnall, TVB-2640, and GSK2194069 | Media | Zebrafish | Cancer | Wistar Institute | LC-MS |
| ST003435 | AN005644 | Metabolomics analysis of zebrafish embryos treated with rotenone, Fasnall, TVB-2640, and GSK2194069 | Media | Zebrafish | Cancer | Wistar Institute | LC-MS |
| ST003434 | AN005641 | Plasma concentrations of Fasnall in mice after a bolus of 10 mg/kg administered intraperitoneally. | Blood | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003434 | AN005642 | Plasma concentrations of Fasnall in mice after a bolus of 10 mg/kg administered intraperitoneally. | Blood | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003433 | AN005639 | Intracellular and medium metabolomics of BT-474 cells treated with dimethylmalonate, Fasnall, and GSK2194069 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003433 | AN005640 | Intracellular and medium metabolomics of BT-474 cells treated with dimethylmalonate, Fasnall, and GSK2194069 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003432 | AN005637 | Intracellular and medium metabolomics of BT-474 cells treated with LW6 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003432 | AN005638 | Intracellular and medium metabolomics of BT-474 cells treated with LW6 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003431 | AN005635 | Metabolomics analysis of breast cancer cell lines treated with dimethylmalonate (DMM), GSK2194069, and their combination. | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003431 | AN005636 | Metabolomics analysis of breast cancer cell lines treated with dimethylmalonate (DMM), GSK2194069, and their combination. | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003430 | AN005633 | Intracellular and medium metabolomics of BT-474 cells treated with GSK2194069 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003430 | AN005634 | Intracellular and medium metabolomics of BT-474 cells treated with GSK2194069 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003429 | AN005631 | Intracellular and medium metabolomics of BT-474 cells treated with Fasnall that was manufactured by Enamine | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003429 | AN005632 | Intracellular and medium metabolomics of BT-474 cells treated with Fasnall that was manufactured by Enamine | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003428 | AN005629 | Intracellular and medium metabolomics of BT-474 cells treated with rotenone | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003428 | AN005630 | Intracellular and medium metabolomics of BT-474 cells treated with rotenone | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003427 | AN005627 | Intracellular and medium metabolomics of BT-474 cells treated with dimethylmalonate | Breast cancer cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003427 | AN005628 | Intracellular and medium metabolomics of BT-474 cells treated with dimethylmalonate | Breast cancer cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003412 | AN005604 | Intracellular and medium metabolomics for BT-474 cells treated with cerulenin, TVB-2640, and TVB-3166 for 24 h | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003412 | AN005605 | Intracellular and medium metabolomics for BT-474 cells treated with cerulenin, TVB-2640, and TVB-3166 for 24 h | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003411 | AN005602 | Intracellular and medium metabolomics for BT-474 cells treated with a range of C75 concentrations for 24 h (C75 MRM included) | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003411 | AN005603 | Intracellular and medium metabolomics for BT-474 cells treated with a range of C75 concentrations for 24 h (C75 MRM included) | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003367 | AN005518 | Intracellular and medium metabolomics for BT-474 cells treated with a range of C75 concentrations for 24 h | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003367 | AN005519 | Intracellular and medium metabolomics for BT-474 cells treated with a range of C75 concentrations for 24 h | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003366 | AN005516 | Malate dehydrogenase (MDH) inhibition assay: Fasnall does not affect MDH activity in vitro | Synthetic | Zebrafish | Cancer | Wistar Institute | LC-MS |
| ST003366 | AN005517 | Malate dehydrogenase (MDH) inhibition assay: Fasnall does not affect MDH activity in vitro | Synthetic | Zebrafish | Cancer | Wistar Institute | LC-MS |
| ST003365 | AN005514 | Intracellular and medium metabolomics for BT-474 breast cancer cells treated with a range of Fasnall and GSK2194069 concentrations for 24 h | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003365 | AN005515 | Intracellular and medium metabolomics for BT-474 breast cancer cells treated with a range of Fasnall and GSK2194069 concentrations for 24 h | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003327 | AN005451 | Control Of Major Bleeding After Trauma (COMBAT) Clinical Research Trial Metabolomics | Blood | Human | Trauma | University of Colorado Anschutz Medical Campus | LC-MS |
| ST002809 | AN004568 | Role of cilia in mitochondrial function | Cultured cells | Dog | Kidney disease | Medical University of South Carolina | LC-MS |
| ST002809 | AN004568 | Role of cilia in mitochondrial function | Cultured cells | Mouse | Kidney disease | Medical University of South Carolina | LC-MS |
| ST002761 | AN004487 | Metabolic responses of normal rat kidneys to a high salt intake (Urine) | Urine | Rat | Medical College of Wisconsin | LC-MS | |
| ST002555 | AN004207 | Ethnicity-Specific Differences in Ovarian Cancer Metabolic Signatures | Cultured cells | Human | Cancer | University of Oklahoma Health Sciences Center | LC-MS |
| ST002505 | AN004127 | A Mammalian Conserved Circular RNA CircLARP2 Regulates Hepatocellular Carcinoma Metastasis and Lipid Metabolism (Part 1) | Cultured cells | Human | Cancer | University of Science and Technology of China | LC-MS |
| ST002447 | AN003988 | Bioactive molecule(s) of gut bacteria of Crocodile (Crocodylus palustris) as potential pharmaceuticals | Bacterial cells | Pseudomonas aeruginosa | Bacterial infection | Sharjah Institute for Medical Research | LC-MS |
| ST002399 | AN003906 | Metabolomics of Adipocyte-Conditioned Media Compared to Stromal Cell- and Un-conditioned Media | Cultured cells | Mouse | Obesity | Emory University | LC-MS |
| ST002322 | AN003789 | Metabolomics study comparing SCAP KO and WT B cells | Cultured cells | Mouse | Indiana University School of Medicine | LC-MS | |
| ST002307 | AN003769 | Metabolomics profiling of the secondary fractions 4 of bacterial culture supernatants. | Bacterial cells | Bacillus megaterium | Myalgic encephalomyelitis/chronic fatigue syndrome | University of Connecticut | LC-MS |
| ST002307 | AN003769 | Metabolomics profiling of the secondary fractions 4 of bacterial culture supernatants. | Bacterial cells | Enterococcus faecium | Myalgic encephalomyelitis/chronic fatigue syndrome | University of Connecticut | LC-MS |
| ST002306 | AN003768 | Metabolomics profiling of full extracts of bacterial culture supernatants. | Bacterial cells | Bacillus megaterium | Myalgic encephalomyelitis/chronic fatigue syndrome | University of Connecticut | LC-MS |
| ST002306 | AN003768 | Metabolomics profiling of full extracts of bacterial culture supernatants. | Bacterial cells | Enterococcus faecium | Myalgic encephalomyelitis/chronic fatigue syndrome | University of Connecticut | LC-MS |
| ST002281 | AN003725 | Metabolite patterns between isogenic normal hiPSCs and Trisomy hiPSC | iPSC cells | Human | Down syndrome | Guangdong Provincial People's Hospital | APCI-MS |
| ST002094 | AN003420 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | LC-MS |
| ST001983 | AN003234 | Metabolomic Fingerprinting of Human High Grade Serous Ovarian Carcinoma Cell Lines | Ovarian cancer cells | Human | Cancer | University of Oklahoma Health Sciences Center | LC-MS |
| ST001404 | AN002346 | Ontogeny related changes in the pediatric liver metabolome (part-III) | Liver | Human | Moffitt Cancer Center | LC-MS | |
| ST001403 | AN002345 | Ontogeny related changes in the pediatric liver metabolome (part-II) | Liver | Human | Moffitt Cancer Center | LC-MS | |
| ST001402 | AN002344 | Ontogeny related changes in the pediatric liver metabolome | Liver | Human | Moffitt Cancer Center | LC-MS | |
| ST000976 | AN001597 | GC6-74 matabolomic of TB (Part 3: Plasma_RPMI) | Blood | Human | Tuberculosis | Max Planck Institute for Infection Biology | LC-MS |
| ST000974 | AN001595 | GC6-74 matabolomic of TB (Part 1: Plasma) | Blood | Human | Tuberculosis | Max Planck Institute for Infection Biology | LC-MS |
| ST000422 | AN000670 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | LC-MS |
| ST000286 | AN000454 | Mouse skeletal myotube chronic low-frequency stimulation | Myotubes | Mouse | University of Florida | LC-MS | |
| ST000286 | AN000455 | Mouse skeletal myotube chronic low-frequency stimulation | Myotubes | Mouse | University of Florida | LC-MS | |
| ST000242 | AN000375 | Whole unconditioned medium (Defined culture media, M199),Whole M1 medium,Whole M2 medium | Macrophages | Human | Mayo Clinic | LC-MS | |
| ST000242 | AN000376 | Whole unconditioned medium (Defined culture media, M199),Whole M1 medium,Whole M2 medium | Macrophages | Human | Mayo Clinic | LC-MS | |
| ST000242 | AN000377 | Whole unconditioned medium (Defined culture media, M199),Whole M1 medium,Whole M2 medium | Macrophages | Human | Mayo Clinic | LC-MS | |
| ST000242 | AN000378 | Whole unconditioned medium (Defined culture media, M199),Whole M1 medium,Whole M2 medium | Macrophages | Human | Mayo Clinic | LC-MS | |
| ST000047 | AN000082 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | LC-MS |
| ST000047 | AN000083 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | LC-MS |
| ST000046 | AN000078 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | LC-MS |
| ST000046 | AN000079 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | LC-MS |
